Compare PLOW & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLOW | CGEM |
|---|---|---|
| Founded | 1948 | 2016 |
| Country | United States | United States |
| Employees | 1764 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.7M | 794.7M |
| IPO Year | 2010 | 2020 |
| Metric | PLOW | CGEM |
|---|---|---|
| Price | $42.65 | $13.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $51.50 | $30.11 |
| AVG Volume (30 Days) | 251.0K | ★ 702.8K |
| Earning Date | 05-04-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $656,053,000.00 | N/A |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $5.36 | $79.85 |
| P/E Ratio | $20.57 | ★ N/A |
| Revenue Growth | ★ 15.40 | N/A |
| 52 Week Low | $21.30 | $5.68 |
| 52 Week High | $47.16 | $16.74 |
| Indicator | PLOW | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 50.57 |
| Support Level | $28.65 | $11.43 |
| Resistance Level | $47.16 | $16.74 |
| Average True Range (ATR) | 1.21 | 0.89 |
| MACD | -0.38 | -0.28 |
| Stochastic Oscillator | 46.76 | 32.06 |
Douglas Dynamics Inc is a manufacturer and upfitter of commercial vehicle attachments and equipment. The Company's portfolio includes snow and ice management attachments sold under the BLIZZARD, FISHER, HENDERSON, SNOWEX, and WESTERN brands, turf care equipment under the TURFEX brand, and industrial maintenance equipment under the SWEEPEX brand. The Company's portfolio also includes the upfit of attachments and storage solutions under the HENDERSON brand, and the DEJANA brand and its related sub-brands. The Company also leases fifteen manufacturing upfit and service facilities located in Iowa, Maryland, Missouri, New Jersey, New York, Ohio, Pennsylvania, and Rhode Island. The Company conducts business in two segments: Work Truck Attachments and Work Truck Solutions.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.